| 摘要 |
Disclosed herein are N-substituted-hexahydro-1,2,5-triazepines of formula I, which is <IMAGE> I or a pharmaceutically acceptable acid addition salt thereof, wherein R4 and R5 are independently hydrogen or C1-C4 alkyl; R1 is (R6)2-CH-(CH2)n- in which n is 0, 1, 2 or 3 and R6 is p-fluoro, chloro or methoxyphenyl; and R3 is hydrogen and R2 is benzoyl, 2,6-dimethyl or diethylbenzoyl, 2,6-dichlorobenzoyl, N-methyl, ethyl or propylcarboxamido, N-phenylcarboxamido, N-2,6-dimethyl or diethylphenylcarboxamido, N-2,6-dichlorophenylcarboxamido, N-methyl, ethyl or propylacetamido, N-phenylacetamido, N-2,6-dimethyl or diethylphenylacetamido, or N-2,6-dichlorophenylacetamido or R2 and R3 are the same and are N-methyl, ethyl or propylcarboxamido, benzoyl, 2,6-dimethyl or diethlbenzoyl, 2,6-dichlorobenzoyl, benzyl, 2,6-dimethyl or diethlbenzoyl, 2,6-dichlorobenzoyl, or a removable amino protective group. Also disclosed are N-substituted-hexahydro-1,2,5-triazepines of formula II in which R1 of formula I is replaced by R7 which is C1-C4 alkyl, and R2 and R3 of formula I are replaced by R8 and R9 which are, respectively, N-2,6-dimethyl, diethyl or dichlorophenylcarboxamido or N-2,6-dimethyl, diethyl or dichlorophenylacetamido and hydrogen. The compounds of the invention have antiarrhythmic properties or are intermediates for the preparation thereof.
|
